The Technical Analyst
Acutus Medical, Inc. [AFIB]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Acutus Medical, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.90% $0.167
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.95 mill |
| EPS: | -0.410 |
| P/E: | -0.410 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 29.72 mill |
| Avg Daily Volume: | 1.069 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.410 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.410 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.147 - 0.187 ( +/- 11.98%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Mukai Takeo | Sell | 8 475 | Form 4 |
| 2024-02-06 | Sohn Tom | Sell | 7 582 | Form 4 |
| 2024-02-01 | Mukai Takeo | Sell | 2 869 | Form 4 |
| 2024-02-01 | Sohn Tom | Sell | 5 709 | Form 4 |
| 2024-01-07 | Mathews Kevin | Sell | 6 342 | Form 4 |
| INSIDER POWER |
|---|
| 71.60 |
| Last 99 transactions |
| Buy: 5 106 118 | Sell: 663 964 |
Forecast:
16:00 - $0.167
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.167
Forecast 2: 16:00 - $0.167
Forecast 3: 16:00 - $0.167
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.167 (1.90% ) |
| Volume | 0.244 mill |
| Avg. Vol. | 1.069 mill |
| % of Avg. Vol | 22.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AFIB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Latest Press Releases
2024-04-01 16:05:00 - Press Release
Acutus Medical Reports Fourth Quarter And Full Year 2023 Financial Results
Carlsbad, calif., april 01, 2024 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib) today reported results for the fourth quarter and full year ended december 31,2023.
2023-11-10 16:01:00 - Press Release
Acutus Medical To Cancel Third Quarter 2023 Conference Call
Carlsbad, calif., nov. 10, 2023 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib), today announced that, following the company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on november 8, 2023, the company will no longer hold its third quarter results conference call and webcast which was previously scheduled for monday, november 13, 2023.
2023-11-08 16:01:00 - Press Release
Acutus Medical Reports Third Quarter 2023 Financial Results
Carlsbad, calif., nov. 08, 2023 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib) today reported results for the third quarter of 2023.
2023-11-08 16:00:00 - Press Release
Acutus Medical Announces Strategic Realignment Of Resources And Corporate Restructuring
Carlsbad, calif., nov. 08, 2023 (globe newswire) -- acutus medical, inc. (“acutus” or the “company”) (nasdaq: afib), today announced a realignment of resources and corporate restructuring.
2023-11-02 16:13:00 - Press Release
Acutus Medical To Announce Third Quarter 2023 Financial Results
Carlsbad, calif., nov. 02, 2023 (globe newswire) -- acutus medical, inc. (“acutus”) (nasdaq: afib), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on monday, november 13, 2023. in conjunction with the release, acutus will host a conference call and webcast that day at 1:30 p.m. pacific time / 4:30 p.m. eastern time to discuss its financial results and recent highlights.
Latest News
2023-11-17 07:26:55 - Benzinga
Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-11-10 16:01:00 - GlobeNewsWire
Acutus Medical to Cancel Third Quarter 2023 Conference Call
CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023.
2023-11-02 16:13:00 - GlobeNewsWire
Acutus Medical to Announce Third Quarter 2023 Financial Results
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
2023-08-07 22:02:07 - Seeking Alpha
Acutus Medical, Inc. (AFIB) Q2 2023 Earnings Call Transcript
Acutus Medical, Inc. (NASDAQ:AFIB ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 AM ET Company Participants Caroline Corner - IR David Roman - CEO Takeo Mukai - CFO Conference Call Participants Marie Thibault - BTIG John Young - Canaccord Genuity Margaret Kaczor - William Blair Operator Good day, and thank you for standing by, and welcome to the Acutus Medical Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
2023-08-07 18:54:20 - Zacks Investment Research
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
Acutus Medical, Inc. (AFIB) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to earnings of $0.16 per share a year ago.
2023-05-11 23:38:06 - Seeking Alpha
Acutus Medical, Inc. (AFIB) Q1 2023 Earnings Call Transcript
Acutus Medical, Inc. (NASDAQ:AFIB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Roman - President & Chief Executive Officer Takeo Mukai - Vice President of Finance & Accounting, Interim Chief Financial Officer Conference Call Participants John Young - BTIG Marie Thibault - BTIG Operator Good afternoon and thank you for standing by. Welcome to the Acutus Medical First Quarter 2023 Conference Call.
2023-04-28 17:15:00 - GlobeNewsWire
Acutus Medical to Announce First Quarter 2023 Financial Results
CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
2023-03-16 21:12:04 - Seeking Alpha
Acutus Medical, Inc. (AFIB) Q4 2022 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:14 PM ET Acutus Medical, Inc. (NASDAQ:AFIB ) Q4 2022 Earnings Conference Call March 16, 2023, 16:30 PM ET Company Participants David Roman - President and CEO Takeo Mukai - VP, Finance & Accounting, Interim CFO Caroline Corner - IR Conference Call Participants Marie Thibault - BTIG Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Operator Thank you for standing by. Welcome to Acutus Medical's Fourth Quarter and Full Year 2022 Earnings Call.
2023-03-16 19:05:49 - Zacks Investment Research
Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-09 16:01:00 - GlobeNewsWire
Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.